Very telling presentation yesterday, if you listen to Dr. West's last remarks it basically gives it away....the near term future of regen medicine that is.
Here is the jist of what he said:
"Biotime has earlier ips filings than Dr. Shinya Yamanaka. Whith that he goes on to say that ips or cell reprogramming will most likely not be the major part of regen medicine in our life time. To reprogram a patients cells there are many stages that the process has to go through, way more than hESC's, and it has to be repeated on an individual babis, so this in the short term will not be feasible given all the FDA hurdles."
Then goes on to briefly say that Biotimes aim has been and remains hESC, off the self products that will likely be the way regen medicine will go and that Biotimes 600+ patent estate covers many areas of disease and that this vast IP of progenitor cells will soon have additional partners besides TEVA.